Home / Generics / General / Extortionate increases in prices of 32 drugs a result of loophole in NHS pricing structure

Extortionate increases in prices of 32 drugs a result of loophole in NHS pricing structure Posted 05/08/2016

An investigation by The Times has exposed a small group of UK-based entrepreneurs to have profited vast amounts of money from hiking up the costs of 32 medicines for common conditions by GBP 262 million a year, a 12,500% increase.

The millionaire businessmen are taking advantage of a loophole that enables them to levy ‘extortionate’ price increases on drugs if an existing brand-named drug is replaced with a generic version instead.

The Times investigation found that four companies have been buying up rights to off-patent drugs no longer considered to be profitable by the bigger pharmaceutical companies. They have purchased the marketing rights, dropped the well-known brand name, and used the new drug name to bypass National Health Service (NHS) pricing controls.

The companies at the centre of the allegation were named by The Times as Atnah, Amdipharm (linked to Asian businessmen Bhikhu and Vijay Patel), Mercury Pharma and Auden McKenzie. Amdipharm and Mercury Pharma were taken over and merged by a European private equity firm in 2012, but sold it at a huge profit following further price rises.

A Department of Health spokesmen said that ‘No pharmaceutical company should be exploiting the NHS. The Competition and Markets Authority is already investigating a potential abuse of generics pricing, and as part of a public consultation we have asked for views on government powers to limit the prices of generic medicines where there is no competitive market’.

Related articles
Prices of brand-name drugs in the US have doubled since 2011

UK's competition authority fines GSK for pay-to-delay

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2016 Pro Pharma Communications International. All Rights Reserved.

Comments (0)

Generics News Research General

more

Biosimilars News Research General

more